Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study

COPD Clinical Trial

— TriNEXT  

Official title:

Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05948891
• Other study ID #: NIS 723
• Status: Recruiting
• Start date: August 1, 2023
• Est. completion date: March 2025

Study information

• Verified date: March 2024
• Source: Chiesi SAS
• Contact: Christine Contré, Dr - Medical Director
• Phone: +33147684121
• Email: c.contre[@]chiesi.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational, prospective, multicentric, cohort study conducted in France to evaluate the QoL in COPD patients treated with TRIMBOW NEXThaler 88/5/9 in a routine clinical practice setting. Patients enrolled in this study will be patients diagnosed with a COPD with a ratio of post-bronchodilator (salbutamol 400 μg) forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7 to whom TRIMBOW NEXThaler 88/5/9 has been initiated by an hospital or local pulmonologists in accordance with clinical practice and marketing authorization.

Description:

The decision of patients to participate in this study must not, in any way, impact upon the standard of care that they are receiving or any benefits to which they are otherwise entitled. The treatment decision must have been taken prior to and independently of the patient's inclusion in the study. All aspects of treatment and clinical management of patients will be at the discretion of the participating pulmonologist (or treating pulmonologist where different) according to local clinical practice and applicable local regulations. In addition to the data available per clinical practice, the participating pulmonologists will be asked to obtain patient-reported outcome measures (PROMs) data from patients within this study and to invite patients to wear a connected watch to record physical activity and sleep quality (50% of patients (about 250 patients) who first accept to wear the watch will be equipped). The duration of a patient's participation in this study will be 6 months made of three visits (M0, M3, M6) according to routine clinical practice. - Visit 1 (M0); inclusion of patient when BDP/FF/GB NEXThaler® 88/5/9 is initiated; - Visit 2 (M3); 3 months (+/- 30 days) post BDP/FF/GB NEXThaler® 88/5/9 initiation; - Visit 3 (M6, last visit): 6 months (+/- 30 days) post BDP/FF/GB NEXThaler® 88/5/9 initiation; The inclusion duration will be 12 to 15 months. The overall duration of the study, including recruitment and follow-up, is expected to be 21 months. Data collection will be considered complete for a participating patient if data available at 6 have been recorded in the CRF and associated PROs completed. Patients will be followed until the end of the study period (M6) even if TRIMBOW NEXThaler 88/5/9 is discontinued.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients aged =40 years
• Diagnosis of COPD with a ratio of post-bronchodilator (salbutamol 400 µg) forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7
• Physicians' decision to start a first prescription fixed triple therapy with BDP/FF/GB NEXThaler® 88/5/9 in accordance with the marketing authorization
• COPD Assessment Test (CAT) total score of at least 10 at the day of inclusion
• Informed consent to participate in the study

Exclusion Criteria:

• Asthmatic patients
• Patients with moderate or severe exacerbations within the 4 weeks prior to enrolment
• Patients treated with fixed triple therapies within 6 months prior inclusion
• Patients receiving pulmonary rehabilitation within 3 months prior to inclusion or within 6 months after inclusion
• Concomitant participation in experimental clinical studies/investigations or participation in experimental clinical studies/investigations within 3 months prior to enrolment into the present study

Related Conditions & MeSH terms

• COPD
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)
observational, prospective, multicentric, international, cohort study

Locations

Country	Name	City	State
France	Pitié-Salpêtrière Hospital	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Chiesi SAS	Kappa Santé

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlation between exacerbations occurrence and physical activity	To assess the association between exacerbations occurrence and physical activity changes; Physical activity measured by a connected device over a 6-month follow-up	Month 6
Other	Correlation between exacerbations occurrence and sleep quality	To assess the association between exacerbations occurrence sleep quality changes; Sleep quality changes measured by a connected device over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device for COPD	Month 6
Other	Correlation between QoL measured by VQ11 and the CAT through PROM	To assess the correlation between QoL measured with the VQ11 and the CAT for COPD; • Endpoints are value of the Pearson correlation test described at baseline, M3 and M6	Month 0, Month 3 and Month 6
Other	Correlation between QoL measured with the VQ11 and Dyspnea-12 through PROM	To assess the correlation between QoL measured with the VQ11 and Dyspnea-12 for COPD; • Endpoints are value of the Pearson correlation test described at baseline, M3 and M6	Month 0, Month 3 and Month 6
Other	Among patients with the connected device, assess the correlation of sleep quality when measured with connected device and with the Pittsburgh Sleep Quality Index	Among COPD patients with the connected device, to assess the correlation of sleep quality when measured with connected device and with the Pittsburgh Sleep Quality Index; • Endpoints are value of the Pearson correlation test described at baseline, M3 and M6	Month 0, Month 3 and Month 6
Other	Dyspnoea with modified Medical Research Council (mMRC)	Endpoint is mMRC total score described at baseline, M3 and M6	Month 0, Month 3 and Month 6
Primary	Change of quality of life through CAT (COPD assessement tool) over 6 month period	To assess change in QoL using the CAT scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device; • Primary endpoint is the proportion of patients achieving a =2-point reduction in CAT total score (MCID) at M6 compared to baseline.	Month 6
Secondary	Mean change Quality of life through VQ11 questionnaire	To assess change in QoL using the VQ11 scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device; • Endpoint is mean VQ11 total score and sub scores described at baseline, M3 and M6	Month 0, Month 3 and Month 6
Secondary	Proportion of patients achieving a =2-point reduction in VQ11 total score	To assess change in QoL using the VQ11 scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device; • Endpoint is the proportion of patients achieving a =2-point reduction in VQ11 total score (MCID) at M3 and M6 compared to baseline.	Month 0, Month 3 and Month 6
Secondary	Mean change in Dyspnoea throught "Dyspnea-12 questionnaire"	To assess changes in dyspnoea using the Dyspnea-12 over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device; • Endpoint is D-12 total score and sub scores described at baseline, M3 and M6	Month 0, Month 3 and Month 6
Secondary	Proportion of patients achieving a 3-point reduction in "Dyspnea-12" total score	To assess changes in dyspnoea using the Dyspnea-12 over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device; • Endpoint is the proportion of patients achieving a 3-point reduction in D-12 total score (MCID) at M3 and M6 compared to baseline.	Month 0, Month 3 and Month 6
Secondary	Rate of moderate and severe exacerbations at M0, M3 and M6 through eCRF	To describe the occurrence of moderate to severe exacerbations over a 6- month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device; Endpoint is the proportion of patients with at least a moderate or severe exacerbation (overall and in each category), at baseline (in the previous 12 months), M3 and M6	Month 0, Month 3 and Month 6
Secondary	Proportion of patients achieving an increase in physical activity throught the a connected device	To assess changes in physical activity using a connected watch over a 6-month; • Endpoint is the proportion of patients achieving an increase in physical activity (= 10%-increase in the mean daily number of step) at M3 and M6 compared to baseline.; Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing watch over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device	Month 0, Month 3 and Month 6
Secondary	Mean daily number of steps throught the a connected device	To assess changes in physical activity using a connected watch over a 6-month; • Endpoints are the mean daily number of steps and the mean of number of steps during 7 days at M0, M3 and M6; Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing watch over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device	Month 0, Month 3 and Month 6
Secondary	Sleep quality throught the Pittsburgh questionnaire	• Endpoints are the Pittsburgh questionnaire at M0, M3 and M6; Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing.	Month 0, Month 3 and Month 6
Secondary	Sleep quality throught the a connected device	To assess changes in sleep quality using a connected device; • Endpoints are the mean daily sleep time, the mean of sleep time and the mean daily number of awakenings during 7 days at M0, M3 and M6; Baseline sleep quality (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing.	Month 0, Month 3 and Month 6
Secondary	Treatment compliance at M3 and M6 through TAI (test inhaler adherence) questionnary	To assess treatment compliance with BDP/FF/G (88/5/9) in NEXThaler® device; • Endpoint is the description of treatment compliance global score at M3 and M6 for COPD using TAI	Month 3 and Month 6
Secondary	Baseline description of sociodemographic data and medical data through eCRF	to describe COPD patient, disease and treatment characteristics at initiation of BDP/FF/G (88/5/9) in NEXThaler® device; Endpoints are description of sociodemographic (age, sex, weight, height, education level, occupation), medical data (risk factors exposure including tobacco, disease history) and lung function data (FEV1, FVC, RV, TLC) at baseline; Endpoints are description of comorbidities and associated treatment throughout the study at baseline; Endpoints are description of previous COPD-related treatment at baseline through eCRF	baseline
Secondary	Treatment tolerance throughout the study through eCRF	To assess treatment tolerance in COPD patients treated with with BDP/FF/G (88/5/9) in NEXThaler® device To assess patient satisfaction with treatment in COPD patients treated with BDP/FF/GB NEXThaler® 88/5/9	up to 24 weeks